Clinical Study

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

Gemma Bruera,1,2 Katia Cannita,1 Aldo Victor Giordano,3 Rosa Manetta,3 Roberto Vicentini,4 Sergio Carducci,3 Patrizia Saltarelli,5 Nerio Iapadre,6 Gino Coletti,7 Corrado Ficorella,1,2 and Enrico Ricevuto1,2

1 Medical Oncology, S. Salvatore Hospital, University of L’Aquila, 67100 L’Aquila, Italy
2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, Italy
3 Radiology, S. Salvatore Hospital, 67100 L’Aquila, Italy
4 Hepatobiliary-Pancreatic Surgery, S. Salvatore Hospital, 67100 L’Aquila, Italy
5 Gastroenterology, S. Salvatore Hospital, 67100 L’Aquila, Italy
6 Infective Disease, S. Salvatore Hospital, 67100 L’Aquila, Italy
7 Pathology, S. Salvatore Hospital, 67100 L’Aquila, Italy

Correspondence should be addressed to Enrico Ricevuto; enrico.ricevuto@univaq.it

Received 7 November 2013; Revised 3 February 2014; Accepted 25 March 2014; Published 8 May 2014

Academic Editor: Wei Mike Liu

Copyright © 2014 Gemma Bruera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Hepatocellular carcinoma (HCC) patients require different treatment strategies according to disease extension, liver function, and patient’s fitness. We evaluated HCC multidisciplinary management in clinical practice. Methods. Consecutive patients were followed and treated with tailored medical, locoregional, and surgical treatments, according to disease stage and patient’s fitness (age, Cumulative Illness Rating Scale (CIRS)). Activity, efficacy, and safety were evaluated. Results. Thirty-eight patients were evaluated: median age, 74; elderly 92%; CIRS secondary 28 (74%); Child-Pugh A 20 (53%), B 11 (29%); and Barcelona Clinic Liver Cancer (BCLC) 0 2 (5%), A 9 (24%), B 10 (26%), C 13 (34%), and D 4 (11%). Overall survival (OS) was 30 months. At 9 months median follow-up, among 25 unresectable HCC, OS was 10 months; BCLC B–D unfit for sorafenib showed OS 3 months. Ten patients (40%) received sorafenib: Child-Pugh A 5 (50%) and B 5 (50%) and disease control rate 89%, progression-free survival 7 months, and OS 9 months. G3-4 toxicities: anorexia, hypertransamininaemia, hyperbilirubinemia, and hypercreatininemia. Limiting toxicity syndromes were 40%, all multiple sites. Conclusion. HCC patients require multidisciplinary clinical management to properly select tailored treatments according to disease stage, fitness, and liver function. Patients suitable for sorafenib should be carefully selected, monitored for individual safety, and prevalently characterized by limiting toxicity syndromes multiple sites.

1. Introduction

Hepatocellular carcinoma (HCC) is a highly aggressive disease; only 10–20% of patients are candidates for curative surgery. In Western countries, the disease is diagnosed at early stages in 30–40% cases and is amenable to potentially curative treatments, such as surgical resection and liver transplantation and locoregional radiofrequency ablation [1]. Therapeutic options are stage dependent. Five-year survival up to 60–70% can be achieved in selected patients [1]. Reasons for tumor unresectability include coexisting advanced cirrhosis, large primary lesion, multifocal disease, invasion and thrombosis of major blood vessels, poor hepatic reserve, and extrahepatic metastases. Disease that is diagnosed at an advanced stage or progressing after locoregional therapy has a dismal prognosis, owing to the underlying liver disease and lack of effective treatment options. Approximately 80% have unresectable tumors, and the prognosis is very poor, with a median survival of only 4 months [2]. Treatment options for unresectable HCC may include locoregional [3–9] and systemic [10] therapy. Transarterial chemoembolization can increase survival in randomized studies, in a minority of patients. Thus, for the majority of HCC patients with unresectable tumors, best supportive care and systemic
chemotherapy remain the main options for palliative treatment.

First line monochemotherapy, or more intensive regimens, reported overlapping activity and efficacy in phase III trials, ranging between objective response rate (ORR) 10–20.9% and overall survival (OS) 4–8.7 months [11, 12]. Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC [13]. Anthracyclines (i.e., doxorubicin) have been the most effective drugs, yielding up to 20% ORR, and 4 months median OS [11]. Cisplatin, interferon, doxorubicin, and fluorouracil (PIAF) used in combination showed promising activity in a phase II study. In a phase III randomized trial, median OS of the doxorubicin and PIAF arms was 6.8 months and 8.7 months ($P = 0.83$) and ORR 10.5% and 20.9%, respectively, not significantly different. Neutropenia, thrombocytopenia, and hypokalemia were significantly more common in patients treated with PIAF [12].

Cellular signalling mediated by the RAF-1 and vascular endothelial growth factor (VEGF) pathways has been implicated in the pathogenesis of HCC [14–17]. Sorafenib is a multikinase inhibitor that targets the RAF/MAP/ERK signalling pathway: it inhibits the serine-threonine kinases implicated in the pathogenesis of HCC [14–17]. Sorafenib was the first agent significantly increasing clinical outcome of advanced HCC [21–23]. A phase 2 study enrolling advanced HCC and Child-Pugh class A or B status indicated a median OS 9.2 months and a median time to progression 5.5 months [21]. Grade 3/4 drug-related toxicities included fatigue (9.5%), diarrhea (8.0%), and hand-foot skin reaction (5.1%). Two phase III trials reported progression-free survival (PFS) 2.8–5.5 months and OS 6.5–10.7 months [22, 23]. Advanced HCC patients, mostly Child-Pugh A, were randomly assigned to sorafenib or placebo. In the SHARP trial, >90% ECOG performance status 0-1 were enrolled and showed median OS significantly longer compared to placebo arm, 10.7 months versus 7.9 months (hazard ratio 0.69); the median time to symptomatic progression did not differ significantly (4.1 and 4.9 months, resp.); median time to radiologic progression was significantly different (5.5 months and 2.8 months, resp.). ORR in the sorafenib group was 2%; disease control rate was significantly higher (43% versus 32%, resp.). In the Asia-Pacific phase III trial [23], patients were more likely to be younger, with HBV-related disease, symptomatic disease, and a higher number of tumor sites. Median OS and median time to progression were lower in both treatment and placebo groups (6.5 versus 4.2 months and 2.8 versus 1.4 months, resp.), even if significantly different (hazard ratio 0.68 and 0.57, resp.).

Clinical management of HCC faces with different options of treatment according to extension of disease, liver functional stage (Child-Pugh class), and patients’ fitness (age, performance status (PS), and comorbidities). In clinical practice, a decision-making process including nutritional, functional, and comorbidity status is required to tailor first line medical treatment with sorafenib in the advanced stage. Elderly HCC patients are prevalent, and primary clinical challenge is proper selection of tailored treatments, according to prognostic factors, and by weighing expected safety and efficacy. Elderly status (age $> 65$ years), PS $> 2$, and/or comorbidities represent major features determining toxicities and limiting quality of life of treated patients, thus limiting indication of sorafenib.

Here we report an experience of multidisciplinary management and selection of tailored multimodality treatment options of consecutive HCC patients in clinical practice, according to defined clinical criteria.

2. Materials and Methods

2.1. Patient Eligibility. Consecutive HCC patients were evaluated by a multidisciplinary disease management team and treated in clinical practice with medical, locoregional, and/or surgical treatments, chosen among those in indication and approved for HCC treatment in different stages. Thus, it was not a clinical trial and any approval by ethics committee and institutional review board was not necessary, because patients were treated with conventional treatments without any additional medical intervention out of the best common clinical practice. Patients had radiological and/or histologically confirmed diagnosis of HCC, age $\geq 18$ years. Patients were classified according to Cumulative Illness Rating Scale (CIRS) [24], Child-Pugh score, and Barcelona Clinic Liver Cancer (BCLC) stage. Treatment options were tailored according to age ($< 75$ years) and patient’s fitness (CIRS). Patients with PS 3 were not treated with sorafenib. Criteria to define patients unfit for standard treatment strategies were uncontrolled severe diseases; cardiovascular disease (uncontrolled hypertension, uncontrolled arrhythmia, and ischemic cardiac diseases in the last year); thromboembolic disease, and coagulopathy, preexisting bleeding diatheses. All patients provided written informed consent to the proposed treatment option. All patients were registered in HCC registry of Regione Abruzzo, Italy (Hepacaregistry), active from September 2010.

2.2. Methods

2.2.1. Treatment Strategies. Medical treatment included sorafenib 400–800 mg/die orally administered, according to patient’s fitness. Locoregional therapy was the conventional transarterial chemoembolization (cTACE), with administration of doxorubicin 30–50 mg.

2.2.2. Study Design. Activity and efficacy were evaluated. Clinical evaluation of response was made by CT scan; RMN was added based on investigators’ assessment. Patients were evaluated at baseline, and every two-three months by a multidisciplinary team, consisting of medical oncologist, radiologist, interventional radiologist, hepatobiliary-pancreatic surgeon, gastroenterologist, infectivologist, and
| Table 1: Patients’ features. |
|-----------------------------|
|                            | Overall patients | Unresectable HCC | Patients treated with sorafenib | Patients untreated with sorafenib |
|                            | Total number (%) | Total number (%) | Total number (%)                | Total number (%)                 |
| Number of patients          | 38              | 25 (66)          | 10 (40)                         | 15 (60)                         |
| Sex                         |                 |                  |                                |                                |
| Male/female                 | 30/8            | 19/6             | 8/2                            | 11/4                            |
| Age, years                  |                 |                  |                                |                                |
| Median                      | 74              | 74               | 73                             | 74                             |
| Range                       | 58–86           | 63–85            | 63–80                          | 65–85                          |
| Elderly                     |                 |                  |                                |                                |
| ≥65 <75 years               | 18 (47)         | 12 (48)          | 4 (40)                         | 8 (53)                         |
| ≥75 years                   | 17 (45)         | 11 (44)          | 5 (50)                         | 6 (40)                         |
| WHO performance status      |                 |                  |                                |                                |
| 0                           | 10 (26)         | 6 (24)           | 4 (40)                         | 2 (13)                         |
| 1                           | 21 (55)         | 13 (52)          | 6 (60)                         | 7 (47)                         |
| 2                           | 6 (16)          | 5 (20)           | —                              | 5 (33)                         |
| 3                           | 1 (3)           | 1 (4)            | —                              | 1 (7)                          |
| CIRS stage                  |                 |                  |                                |                                |
| Primary                     | 2 (5)           | 2 (8)            | —                              | 2 (13)                         |
| Intermediate                | 8 (21)          | 4 (16)           | 2 (20)                         | 2 (13)                         |
| Secondary                   | 28 (74)         | 19 (76)          | 8 (80)                         | 11 (73)                        |
| Liver disease               |                 |                  |                                |                                |
| Hepatitis                   | 9 (24)          | 5 (20)           | 2 (20)                         | 3 (20)                         |
| Cirrhosis                   | 24 (63)         | 18 (80)          | 7 (70)                         | 11 (73)                        |
| Etiology                    |                 |                  |                                |                                |
| HBV                         | 1 (3)           | 1 (4)            | 1 (10)                         | —                              |
| HCV                         | 13 (34)         | 9 (36)           | 2 (20)                         | 7 (47)                         |
| HBV + HCV                   | 1 (3)           | —                | —                              | —                              |
| Alcoholic                   | 15 (39)         | 10 (40)          | 3 (30)                         | 7 (47)                         |
| Idiopathic                  | 8 (21)          | 3 (12)           | 2 (20)                         | 1 (7)                          |
| Complications               |                 |                  |                                |                                |
| Varices                     | 12 (31.5)       | 8 (32)           | 4 (40)                         | 4 (27)                         |
| Thrombosis                  | 7 (18)          | 5 (20)           | 1 (10)                         | 4 (27)                         |
| Splenomegaly                | 14 (37)         | 12 (48)          | 6 (60)                         | 6 (40)                         |
| Laboratory tests            |                 |                  |                                |                                |
| Thrombocytopenia            | 6 (16)          | 5 (20)           | 3 (30)                         | 2 (13)                         |
| Hypertransaminasemia        | 22 (58)         | 19 (76)          | 7 (70)                         | 12 (80)                        |
| Cholestasis                 | 24 (63)         | 21 (84)          | 10 (10)                        | 11 (73)                        |
| Hyperbilirubinemia          | 11 (29)         | 11 (44)          | 5 (50)                         | 6 (40)                         |
| Number of involved sites    |                 |                  |                                |                                |
| 1                           | 24 (63)         | 11 (44)          | 4 (40)                         | 7 (47)                         |
| ≥2                          | 14 (37)         | 14 (56)          | 6 (60)                         | 8 (53)                         |
| Sites of metastases         |                 |                  |                                |                                |
| Lung                        | 3 (8)           | 3 (12)           | 1 (10)                         | 2 (13)                         |
| Lymph nodes                 | 11 (29)         | 11 (44)          | 5 (50)                         | 6 (40)                         |
| Bone                        | 3 (8)           | 3 (12)           | 2 (20)                         | 1 (7)                          |
| Ascites                     | 9 (24)          | 8 (32)           | 3 (30)                         | 5 (33)                         |
| Pleural effusion            | 2 (5)           | 2 (8)            | —                              | 2 (13)                         |
Table 1: Continued.

|                         | Overall patients | Unresectable HCC | Patients treated with sorafenib | Patients untreated with sorafenib |
|-------------------------|------------------|------------------|---------------------------------|----------------------------------|
|                         | Total number (%) | Total number (%) | Total number (%)                | Total number (%)                 |
| Liver nodules           |                  |                  |                                 |                                 |
| Single                  | 9 (24)           | 2 (8)            | —                               | 2 (13)                           |
| Multiple                | 29 (76)          | 23 (92)          | 10 (100)                        | 13 (87)                          |
| Diagnosis               |                  |                  |                                 |                                 |
| Clinical                | 24 (63)          | 19 (76)          | 6 (60)                          | 13 (87)                          |
| Histopathological       | 14 (37)          | 6 (24)           | 4 (40)                          | 2 (13)                           |
| αfetoprotein at DMT     |                  |                  |                                 |                                 |
| evaluation              |                  |                  |                                 |                                 |
| Negative                | 17 (48)          | 6 (24)           | 2 (20)                          | 4 (27)                           |
| Positive                | 3 (8)            | 4 (16)           | 2 (20)                          | 2 (13)                           |
| ≥ 200 ng/mL             | 10 (26)          | 13 (52)          | 6 (60)                          | 7 (47)                           |
| Unknown                 | 8 (21)           | 2 (8)            | —                               | 2 (13)                           |
| Child-Pugh score at DMT |                  |                  |                                 |                                 |
| evaluation              |                  |                  |                                 |                                 |
| A                       | 20 (53)          | 11 (44)          | 5 (50)                          | 6 (40)                           |
| B                       | 11 (29)          | 12 (48)          | 5 (50)                          | 7 (47)                           |
| C                       | 3 (8)            | 2 (8)            | —                               | 2 (13)                           |
| Unknown                 | 4 (10)           | —                | —                               |                                  |
| BCLC stage at DMT       |                  |                  |                                 |                                 |
| evaluation              |                  |                  |                                 |                                 |
| 0                       | 2 (5)            | —                | —                               | —                                |
| A                       | 9 (24)           | 2 (8)            | —                               | 2 (13)                           |
| B                       | 10 (26)          | 7 (28)           | 3 (30)                          | 4 (27)                           |
| C                       | 13 (34)          | 13 (52)          | 6 (60)                          | 7 (47)                           |
| D                       | 4 (11)           | 3 (12)           | 1 (10)                          | 2 (13)                           |
| DMT treatment choice    |                  |                  |                                 |                                 |
| Follow-up               | 11 (29)          | 2 (8)            | —                               | 2 (13)                           |
| Surgery                 | 1 (2)            | —                | —                               | —                                |
| Biopsy                  | 3 (8)            | 3 (12)           | —                               | 3 (20)                           |
| TACE                    | 5 (13)           | 3 (12)           | —                               | 3 (20)                           |
| Sorafenib               | 12 (32)          | 12 (48)          | 10 (100)                        | 2 (13)                           |
| Best supportive care    | 6 (16)           | 5 (20)           | —                               | 5 (33)                           |
| Sorafenib treatment     |                  |                  |                                 |                                 |
| 800 mg/die              | 3 (8)            | 3 (30)           | 3 (30)                          | —                                |
| 600 mg/die              | 3 (8)            | 3 (30)           | 3 (30)                          | —                                |
| 400 mg/die              | 4 (10.5)         | 4 (40)           | 4 (40)                          | —                                |

WHO: World Health Organization; CIRS: Cumulative Illness Rating Scale; TACE: transarterial chemoembolization; DMT: disease management team.

pathologist, sharing and dynamically evaluating common multidisciplinary treatment strategies. Follow-up was scheduled every two-three months up to disease progression or death.

Toxicity was registered according to National Cancer Institute Common Toxicity Criteria (version 4.0). Limiting toxicity (LT) was defined as grade 3-4 nonhematologic toxicity, grade 4 hematologic toxicity, febrile neutropenia, or any toxicity determining >2 weeks delay of medical treatment. To discriminate individual safety, limiting toxicity syndromes (LTS), consisting of at least a LT associated or not to other limiting or G2 toxicities, were evaluated, as previously reported [25, 26]. LTS were classified into limiting toxicity syndromes single site (LTS-ss), characterized only by the LT, and limiting toxicity syndromes multiple sites (LTS-ms), characterized by ≥2 LTs or a LT associated to other, at least G2, nonlimiting toxicities.

Clinical criteria of activity and efficacy were ORR, PFS, and OS: ORR, evaluated according to RECIST criteria [27] and PFS and OS, evaluated using the Kaplan-Meier method [28]. PFS was defined as the length of time from the beginning of treatment and disease progression or death (resulting from
any case) or to the last contact and OS as the length of time between the beginning of treatment and death or to last contact. Log-rank test was used to compare OS [29].

3. Results

3.1. Patient Demographics. From September 2010 to October 2013, 38 new patients were evaluated by the HCC multidisciplinary team at S. Salvatore Hospital, L’Aquila, Italy. Clinical features of patients were (Table 1): male 79%; median age, 74 years; young-elderly 47% and old-elderly 45%; PS 0-1 81%. CIRS stage: primary 5%, intermediate 21%, and secondary 74% (28 patients). Underlying liver disease was hepatitis 24%, cirrhosis 63% (24 patients) and HCV-related 34% and alcoholic 39%. Complications of liver disease were thrombosis 18%, splenomegaly 37%, and varices 31.5%; altered baseline laboratory tests were thrombocytopenia 16% (6 patients), hypertransaminasemia 58%, cholestasis 63%, and hyperbilirubinemia 29%. Involved tumoral sites other than liver were observed in 37% (14 patients): metastatic sites were lung 8%, lymph nodes 29%, bone 8%, ascites 24%, and pleural effusion 5%. Liver nodules were single 24% (9 patients) and multiple 76% (29 patients). Diagnosis of HCC was clinical in 24 patients (63%) and histopathological in 14 (37%). Previous therapies were surgery 9 patients (24%) and TACE 10 (26%). At the time of the multidisciplinary team evaluation: alphafetoprotein negative 17 (48%), positive and TA C E 10 (26%), and histopathology was clinical in 24 patients (63%) and histopathological in 14 (37%).

3.2. Demographics of Patients Treated with Sorafenib. Clinical features of the 10 patients treated with sorafenib were (Table 1): median age, 73 years; young-elderly 47% and old-elderly 45%; PS 0-1 81%. CIRS stage: primary 5%, intermediate 21%, and secondary 74% (28 patients). Underlying liver disease was hepatitis 24%, cirrhosis 63% (24 patients) and HCV-related 34% and alcoholic 39%. Complications of liver disease were thrombosis 18%, splenomegaly 37%, and varices 31.5%; altered baseline laboratory tests were thrombocytopenia 16% (6 patients), hypertransaminasemia 58%, cholestasis 63%, and hyperbilirubinemia 29%. Involved tumoral sites other than liver were observed in 37% (14 patients): metastatic sites were lung 8%, lymph nodes 29%, bone 8%, ascites 24%, and pleural effusion 5%. Liver nodules were single 24% (9 patients) and multiple 76% (29 patients). Diagnosis of HCC was clinical in 24 patients (63%) and histopathological in 14 (37%).

3.3. Overall Activity and Efficacy. Among the overall 38 patients, at a median follow-up of 15.5 months, median OS was 30 months (0–88+): 21 events occurred (Figure 1(a)). Among 25 unresectable HCC, at a median follow-up of 9 months, median OS was 10 months (0–46): 18 events occurred (72%) (Figure 1(b)). Among 15 patients with unresectable HCC or with advanced/metastatic HCC unfit for treatment with sorafenib, median OS was 6 months (0–40+): 11 events occurred (73%). In this subgroup, BCLC B, C, and D HCC patients showed median OS 3 months (0–25), trendily worse compared with BCLC B, C, and D HCC patients treated with sorafenib (P = 0.073) (Figure 1(c)).

3.4. Sorafenib Activity and Efficacy. Among the 10 patients who underwent medical treatment with sorafenib, 9 were evaluable for activity (Table 2). The intent-to-treat analysis showed 2 partial responses (22%), 6 stable diseases (67%), and 1 progressive disease (11%). Disease control rate was 89% (α 0.05, CI ± 22). Median PFS was 7 months (2–34): 8 events occurred (Figure 2(a)). Median OS was 9 months (4–35+): 7 events occurred (Figure 2(b)).

3.5. Dose-Intensity and Toxicity. Median number of cycles per patient was 4 (range 1–9). Median received dose intensity (rDI) per cycle was 315 (124–800) mg/die, 39% of the recommended dose.

G3-4 toxicities, by patients, in 45 cycles, were (Table 3) anorexia 1 (10%); hypertransaminasia, 4 (40%), hyperbilirubinemia, 1 (10%); and hypercreatiniemia, 2 (20%). G2 toxicities were anorexia 3 (30%), diarrhea 4 (40%), constipation 2 (20%), asthenia 5 (50%), epistaxis 2 (20%), hand-foot syndrome 1 (10%), hypertransaminasia, 1 (10%), hyperbilirubinemia, 3 (30%), cholestasis 1 (10%), hypo-roidism 2 (20%), and thrombocytopenia 2 (20%). No case

| Table 2: Activity and efficacy of sorafenib. |
|--------------------------------------------|
| **Intent-to-treat Analysis**               |
| **Number**                  | **%**                       |
| Enrolled patients            | 10                          | 100                        |
| Evaluable patients           | 9                           | 90                         |
| Objective response           | 2                           | 22 (CI ± 29)               |
| Partial response             | 2                           | 22                         |
| Complete response            | —                           | —                          |
| Stable disease               | 6                           | 67                         |
| Progressive disease          | 1                           | 11                         |
| Median progression-free survival, months | 7                          |
| Range                        | 2–34                        |
| Progression events           | 8                           | 80                         |
| Median overall survival, months | 9                      |
| Range                        | 4–35+                       |
| Deaths                       | 7                           | 70                         |

Median overallsurvival, months 9
Median progression-free survival, months 7
Progressive disease 1 11
Stable disease 6 67
Partial response 2 22
Complete response — —
Evaluable patients 9 90
Objective response 2 22 (CI ± 29)
Enrolled patients 10 100

3.5. Dose-Intensity and Toxicity. Median number of cycles per patient was 4 (range 1–9). Median received dose intensity (rDI) per cycle was 315 (124–800) mg/die, 39% of the recommended dose.

G3-4 toxicities, by patients, in 45 cycles, were (Table 3) anorexia 1 (10%); hypertransaminasia, 4 (40%), hyperbilirubinemia, 1 (10%); and hypercreatiniemia, 2 (20%). G2 toxicities were anorexia 3 (30%), diarrhea 4 (40%), constipation 2 (20%), asthenia 5 (50%), epistaxis 2 (20%), hand-foot syndrome 1 (10%), hypertransaminasia, 1 (10%), hyperbilirubinemia, 3 (30%), cholestasis 1 (10%), hypo-roidism 2 (20%), and thrombocytopenia 2 (20%). No case
of thrombosis, hemorrhage/bleeding, cardiac or cerebrovascular ischemia, G4 neutropenia, febrile neutropenia, severe thrombocytopenia, or toxic deaths were observed. LTS were observed in 4 out of 10 patients (40%), all LTS-ms characterized by LT associated to other, at least G2, nonlimiting toxicities (Table 4). LTS were (Table 5) G2 thrombocytopenia for more than 2 weeks associated to G2 neutropenia; G2 hand-foot syndrome associated to G2 anorexia, G2 asthenia, and G2 hypothyroidism; G2 hyperbilirubinemia associated to G2 hypertransaminasemia; and G2 hyperbilirubinemia associated to G3 hypertransaminasemia, G4 cholestasis, G2 hypothyroidism, and G2 diarrhea.

4. Discussion

The present experience of clinical management of consecutive HCC patients by our multidisciplinary team in clinical practice showed that patients were mostly elderly (92%), equivalently young- and old-elderly, and prevalently with CIRS stage secondary (74%), PS 0-1 (81%), an underlying cirrhosis (63%), Child-Pugh A/B 82%, BCLC B-D 71%. Patients with unresectable or advanced/metastatic HCC were 66% mostly (60%) unfit for sorafenib, due to elderly and/or CIRS and/or performance status 3, altered liver functional status, and 40% fit for sorafenib. Median OS of unresectable
or advanced/metastatic HCC was 10 months, and BCLC B–D patients unfit for sorafenib showed trendily worse prognosis (3 months).

HCC patients treated with sorafenib had PS 0-1, Child-Pugh class A and B, and received a median dose intensity 315 mg/die (39%). The present tailored approach, based on evaluation of elderly status and/or CIRS and functional liver status, as prevalently addressing selection of suitable patients and different doses of sorafenib, was associated with a disease control rate 89%, PFS 7 months and OS 9 months that requires further prospective validation. A complex decision-making process discriminating patients’ fitness and tailoring medical treatment is challenging in this disease, mostly affecting elderly patients with comorbidities. Our experience of multidisciplinary and tailored clinical management is in agreement with prospective phase II/III trials evaluating sorafenib in different populations, mostly characterized by Child-Pugh class A, that reported significantly increased PFS 2.8–5.5 months and OS 6.5–10.7 months [21–23]. Subgroup analyses suggested that sorafenib is effective irrespective of the baseline ECOG PS (0–2), tumor burden (presence or absence of macroscopic vascular invasion and/or extrahepatic spread), presence or absence of either lung or lymph nodes metastasis, tumor stage, prior therapy, and disease etiology (alcohol-related or HCV-related HCC) [30, 31]. Child-Pugh class B benefited to the same extent as class A patients in terms of activity and PFS, but with lower OS [32] (3.2 versus 9.5 months) [33–39]. In a large retrospective study, median OS was 5.5 months compared to 11.3 months, respectively [35]. The prospective GIDEON trial confirmed that safety profile and time to progression of sorafenib was generally similar, and median OS was shorter in Child-Pugh class B patients [38, 40], 5.2 months compared to 13.6 months, respectively [40]. In Asian patients with advanced HBV-related HCC, there were no significant differences in clinical benefit, OS (5.5 versus 5 months), grade 3/4 hematologic toxicities.

Randomized studies showed that significantly prevalent grade 3/4 toxicities [22, 23] were weight loss, hand-foot skin reaction (5–11%), diarrhea (6–8%) [22], hypophosphatemia (11%), thrombocytopenia (4%), and fatigue (3.4%). Hand-foot skin reaction and diarrhea were the most common adverse events resulting in dose reductions. Sorafenib-associated adverse events led to dose reductions and interruptions in 26% and 44% of patients, respectively. Grade 3/4 adverse events in the Child-Pugh A and B groups, respectively, included hyperbilirubinemia (14% and 53%), ascites (3% and 5%), and encephalopathy (3% and 13%), and were more frequent in Child-Pugh class B subgroup [34]. In the GIDEON trial, the incidence of adverse events was similar across subgroups, although serious adverse events were more common in Child-Pugh class B patients [40]. In advanced HBV-related HCC, there were no significant differences in grade 3/4 hematologic toxicities and non-hematologic toxicities [41]. In our experience of tailored treatment according to patient’s age and CIRS status and careful safety monitoring, cumulative G3–4 toxicities were anorexia (10%), hypertransaminasemia (40%), hyperbilirubinemia (10%), hypercreatininemia (20%). More, G2 diarrhea was observed in 40%. Elderly HCC patients treated with sorafenib showed 40% individual LTS, previously reported by our group as significantly more frequent in elderly metastatic colorectal cancer patients [25, 26]. LTS were almost exclusively characterized by LTS-ms, mainly including thrombocytopenia, hand-foot syndrome, liver dysfunction, anorexia, asthenia, hypothyroidism, and diarrhea.
Table 3: Cumulative toxicity.

| Patients | Cycles |
|----------|--------|
| Number   | 10     | 45 |
| NCI-CTC Grade | 1 2 3 4 1 2 3 4 |
| Nausea (%) | 1(10) — — — 1(2) — — — |
| Vomiting (%) | 1(10) — — — 1(2) — — — |
| Anorexia (%) | 4(40) 3(30) 1(10) — 6(13) 7(16) — — |
| Diarrhea (%) | 1(10) 4(40) — — 12(27) — — — |
| Hypoalbuminemia (%) | — — — — — — — — |
| Constipation (%) | — 2(20) — — 1(2) 2(4) — — |
| Stomatitis/mucositis (%) | 2(20) — — — 12(27) — — — |
| Anemia (%) | 4(40) 5(50) — — 30(67) 5(11) — — |
| Hypertension (%) | 1(10) — — — 1(2) — — — |
| Hypoproteinemia (%) | — — — — — — — — |
| Gengival recession/gengivitis (%) | — 2(20) — — 1(2) 2(4) — — |
| Rhinitis (%) | 1(10) — — — 1(2) — — — |
| Epistaxis (%) | — 2(20) — — 2(4) 2(4) — — — |
| HFS (%) | — 1(10) — — 3(7) 1(2) — — — |
| Hypertransaminasemia (%) | 2(20) — — — 2(4) — — — |
| Hyperbilirubinemia (%) | 3(30) 1(10) 2(20) 2(20) 14(31) 13(29) 2(4) 1(4) |
| Cholestasis (%) | 4(40) 3(30) 1(10) — 17(38) 5(11) 4(9) — |
| Hyperammoniemia (%) | 2(20) 1(10) 1(10) — 12(27) 11(24) 14(31) 1(2) |
| Hypercreatininemia (%) | 3(30) — — — 5(11) — 2(4) — |
| Hypothyroidism (%) | 2(20) — — — 2(4) — — — |
| Anemia (%) | — 2(20) — — 5(11) 1(2) — — — |
| Leucopenia (%) | 2(20) 1(10) — — 2(4) 1(2) — — — |
| Neutropenia (%) | — 1(10) — — 2(4) 1(2) — — — |
| Thrombocytopeny (%) | 4(40) 2(20) — — 8(18) 6(13) — — — |

Table 4: Distribution of limiting toxicity syndromes.

| Overall | Patients | % |
|---------|----------|---|
| No.     | 10       | 100 |
| Limiting toxicity syndromes (LTS) | 4 40 |
| LTS single-site (LTS-ss) | — — |
| LTS multiple-sites (LTS-ms) | 4 40 |
| Single LT plus G2-3 | 4 40 |
| Double LTs | — — |

LTS: limiting toxicity; G: grade.

cTACE can increase survival in selected patients with inoperable intermediate HCC (BCLC stage B) [1, 3], with 1-, 2-, and 3-year survival of 75%, 47%, and 26%, respectively [1]. After TACE, tumor microenvironment becomes deranged with increased hypoxia, leading to upregulation of hypoxia inducible factor-α, which in turn upregulates VEGF and PDGFR and increases tumor angiogenesis [42, 43], that may have adverse protumor consequences [44, 45]. There has been interest in combining antiangiogenic targeted agents with TACE to decrease post-TACE angiogenesis, to improve the efficacy of locoregional therapy, and to decrease the incidence of systemic disease. Preclinical models combining transarterial embolization with antiangiogenic agents reported a reduction in tumor volume and vessel density, as well as a prolongation in survival compared with transarterial embolization alone [46]. In nonrandomized phase II studies, sorafenib concomitant with TACE or doxorubicin-eluting beads (DEB) TACE was well tolerated and effective in unresectable HCC [47–51]. In a phase III randomized trial, sorafenib when given after TACE did not significantly increase time to progression or OS in patients who responded to TACE, potentially due to delays in starting sorafenib after TACE (median 9 weeks) and/or low daily sorafenib doses [52].

The present experience based on multidisciplinary management in clinical practice of a small cohort of consecutive HCC patients in a single institution to select proper tailored treatment options, based on comorbidity and functional liver status, requires further validation in a wide population. Careful selection of HCC patients suitable for further development of therapeutic strategies in HCC, integrating sorafenib with TACE, and including innovative targeted agents, according to prognostic and predictive biomarkers, is mandatory.
5. Conclusion

In clinical practice, HCC patients require multidisciplinary clinical management and selection of tailored locoregional and medical treatments, according to disease stage and patient’s age and comorbidities. HCC patients suitable for sorafenib treatment should be carefully selected and monitored for individual safety.

Conflict of Interests

The authors declare that they have no competing interests.

Gemma Bruera is a PhD student in Biotechnology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, funded by the University of L’Aquila, Italy.

References

[1] J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003.

[2] A. Pawarode, N. Voravud, V. Sriruanpong, P. Kullavanijaya, and Y. Z. Patt, “Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 21, no. 4, pp. 386–391, 1998.

[3] C.-M. Lo, H. Ngan, W.-K. Tso et al., “Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma,” Hepatology, vol. 35, no. 5, pp. 1164–1171, 2002.

[4] J. M. Llovet, M. I. Real, X. Montaña et al., “Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial,” The Lancet, vol. 359, no. 9319, pp. 1734–1739, 2002.

[5] K. Kotoh, H. Sakai, S. Sakamoto et al., “The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy,” American Journal of Gastroenterology, vol. 89, no. 2, pp. 194–198, 1994.

[6] S. Rossi, E. Buscarini, F. Garbagnati et al., “Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode,” American Journal of Roentgenology, vol. 170, no. 4, pp. 1015–1022, 1998.

[7] M. Sato, Y. Watanabe, S. Ueda et al., “Microwave coagulation therapy for hepatocellular carcinoma,” Gastroenterology, vol. 110, no. 5, pp. 1015–1019, 1996.

[8] K. A. Crews, J. A. Kuhn, T. M. McGarty, T. L. Fisher, R. M. Goldstein, and J. T. Preskitt, “Cryosurgical ablation of hepatic tumors,” American Journal of Surgery, vol. 174, no. 6, pp. 614–618, 1997.

[9] W. Y. Lau, S. Ho, T. W. T. Leung et al., “Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres,” International Journal of Radiation Oncology Biology Physics, vol. 40, no. 3, pp. 583–592, 1998.

[10] T. W. T. Leung and P. J. Johnson, “Systemic therapy for hepatocellular carcinoma,” Seminars in Oncology, vol. 28, no. 5, pp. 514–520, 2001.

[11] H. S. Hochster, M. D. Green, and J. Speyer, “4’Epipodophyllotoxin (Epirubicin): activity in hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 951–958, 1998.

[12] W. Y. Lau, S. Ho, T. W. T. Leung et al., “Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres,” International Journal of Radiation Oncology Biology Physics, vol. 40, no. 3, pp. 583–592, 1998.

[13] M. B. Thomas, J. P. O’Beirne, J. Furuse, A. T. C. Chan, G. Abou-Alfa, and P. Johnson, “Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 1008–1014, 2008.

[14] Y. Ito, Y. Sasaki, M. Horimoto et al., “Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma,” Hepatology, vol. 27, no. 4, pp. 951–958, 1998.

[15] A. Villanueva, P. Newell, D. Y. Chiang, S. L. Friedman, and J. M. Llovet, “Genomics and signaling pathways in hepatocellular carcinoma,” Seminars in Liver Disease, vol. 27, no. 1, pp. 55–76, 2007.

[16] D. F. Calvisi, S. Ladu, A. Gorden et al., “Ubiquitous activation of ras and jak/stat pathways in human HCC,” Gastroenterology, vol. 130, no. 4, pp. 1117–1128, 2006.

[17] D. Semela and J.-F. Dufour, “Angiogenesis and hepatocellular carcinoma,” Journal of Hepatology, vol. 41, no. 5, pp. 864–880, 2004.
[18] S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004.

[19] Y. S. Chang, J. Adnane, P. A. Trail et al., “Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 5, pp. 561–574, 2007.

[20] L. Liu, Y. Cao, C. Chen et al., “Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5,” Cancer Research, vol. 66, no. 24, pp. 11851–11858, 2006.

[21] G. K. Abou-Alfa, L. Schwartz, S. Ricci et al., “Phase II study of sorafenib in patients with advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4293–4300, 2006.

[22] J. M. Llovet, S. Ricci, V. Mazzaferrro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008.

[23] A.-L. Cheng, Y.-K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009.

[24] M. Extermann, J. Overcash, G. H. Lyman, J. Parr, and L. Balducci, “Comorbidity and functional status are independent in older cancer patients,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1582–1587, 1998.

[25] G. Bruer et al., A. Santomaggio, K. Cannita et al., “Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (F1r-B/F0x) in first line treatment of metastatic colorectal cancer: a phase II study,” BMC Cancer, vol. 10, article 567, 2010.

[26] G. Bruer, K. Cannita, A. V. Giordano, R. Vicentini, C. Ficorella, and E. Ricevuto, “Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, F1r-B/F0x, in young-elderly Metastatic Colorectal Cancer patients,” BioMed Research International, vol. 31, no. 15, supplement, p. 4126, 2013.

[27] P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000.

[28] E. L. Kaplan and P. Meier, “Nonparametric estimation of incomplete observations,” Journal of the American Statistical Association, vol. 53, pp. 457–481, 1958.

[29] R. Peto and J. Peto, “Asymptomatically efficient rank invariant test procedures,” Journal of the Royal Statistical Society A, vol. 135, pp. 185–206, 1972.

[30] J. Bruix, J. L. Raoul, M. Sherman et al., “Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial,” Journal of Hepatology, vol. 57, no. 4, pp. 821–829, 2012.

[31] A.-L. Cheng, Z. Guan, Z. Chen et al., “Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial,” European Journal of Cancer, vol. 48, no. 10, pp. 1452–1465, 2012.

[32] J.-L. Raoul, J. Bruix, T. F. Gretan et al., “Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses,” Journal of Hepatology, vol. 56, no. 5, pp. 1080–1088, 2012.

[33] G. K. Abou-Alfa, “Selection of patients with hepatocellular carcinoma for sorafenib,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 4, pp. 397–403, 2009.

[34] G. K. Abou-Alfa, D. Amadori, A. Santoro et al., “Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis,” Gastrointestinal Cancer Research, vol. 4, no. 2, pp. 40–44, 2011.

[35] M. Pinter, W. Sieghart, I. Grazia et al., “Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis,” Oncologist, vol. 14, no. 1, pp. 70–76, 2009.

[36] A. Hollebecque, S. Cattan, O. Romano et al., “Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 10, pp. 1193–1201, 2011.

[37] J. E. Kim, B.-Y. Ryoo, M.-H. Ryu et al., “Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 5, pp. 1285–1290, 2011.

[38] R. Lencioni, M. Kudo, S. L. Ye et al., “First interim analysis of the GIDEON (Global Investigation of Therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeneB) non-interventional study,” International Journal of Clinical Practice, vol. 66, no. 7, pp. 675–683, 2012.

[39] J. Chiu, Y. F. Tang, T.-J. Yao et al., “The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits,” Cancer, vol. 118, no. 21, pp. 5293–5301, 2012.

[40] J. A. Marrero, R. Lencioni, S. L. Ye et al., “Final analysis of Gideon (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma (HCC) and of Its Treatment with Sorafenib (Sor) in >3000 Sor-treated patients (pts) clinical findings in pts with liver dysfunction),” Journal of Clinical Oncology, vol. 31, no. 15, supplement, p. 4126, 2013.

[41] T. Yau, P. Chan, K. K. Ng et al., “Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population,” Cancer, vol. 115, no. 2, pp. 428–436, 2009.

[42] X. Li, G.-S. Feng, C.-S. Zheng, C.-K. Zhuo, and X. Liu, “Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level,” World Journal of Gastroenterology, vol. 10, no. 19, pp. 2878–2882, 2004.

[43] B. Wang, H. Xu, Z. Q. Gao, H. F. Ning, Y. Q. Sun, and G. W. Cao, “Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization,” Acta Radiologica, vol. 49, no. 5, pp. 523–529, 2008.

[44] D.-F. Yao, X.-H. Wu, Y. Zhu et al., “Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma,” Hepatobiliary and Pancreatic Diseases International, vol. 4, no. 2, pp. 220–226, 2005.

[45] C.-S. Tseng, H.-W. Lo, P.-H. Chen, W.-L. Chuang, C.-C. Juan, and C.-G. Ker, “Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma,” Hepato-Gastroenterology, vol. 51, no. 59, pp. 1454–1458, 2004.
[46] H. Jiang, Q. Meng, H. Tan et al., “Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas,” International Journal of Cancer, vol. 121, no. 2, pp. 416–424, 2007.

[47] A. Erhardt, F. T. Kolligs, M. M. Dollinger et al., “TACE plus sorafenib for the treatment of hepatocellular carcinoma: final results of the multicenter SOCRATES trial,” Journal of Clinical Oncology, vol. 29, no. 15, supplement, p. 4107, 2011.

[48] T. M. Pawlik, D. K. Reyes, D. Cosgrove, I. R. Kamel, N. Bhagat, and J.-F. H. Geschwind, “Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 29, no. 30, pp. 3960–3967, 2011.

[49] J.-W. Park, Y. H. Koh, H. B. Kim et al., “Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 6, pp. 1336–1342, 2012.

[50] Y. H. Chung, G. Han, J. H. Yoon et al., “Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma,” International Journal of Cancer, vol. 132, no. 10, pp. 2448–2458, 2013.

[51] R. Lencioni, J. M. Llovet, G. Han et al., “Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial,” Journal of Clinical Oncology, vol. 30, no. 4, supplement, p. LBA154, 2012.

[52] M. Kudo, K. Imanaka, N. Chida et al., “Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma,” European Journal of Cancer, vol. 47, no. 14, pp. 2117–2127, 2011.